Ibrutinib is active in previously treated Waldenstro¨m macroglobulinemia (WM). MYD88 mutations
(MYD88MUT) and CXCR4 mutations (CXCR4MUT) affect ibrutinib response. We report on a prospective
study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect
of… Continue reading
5th International Patient and Physician Summit on Waldenstrom’s Macroglobulinemia (WM).
The Summit will take place on October 13-14, 2018, at the New York Marriott Downtown Hotel and Conference Center, situated in Lower Manhattan next to the Freedom Tower. The… Continue reading